General Terms Contract Clauses (167)

Grouped Into 2 Collections of Similar Clauses From Business Contracts

This page contains General Terms clauses in business contracts and legal agreements. We have organized these clauses into groups of similarly worded clauses.
General Terms. Unless previously converted into shares of the common stock, $0.00001par value, of Shuttle Pharma or the common stock of any successor in interest to the Maker (each the "Common Stock") as contemplated hereby, this Note, together with all accrued interest hereon at the Interest Rate, shall be due and payable on the earlier of the Company's completion of its IPO (as defined below) or July 31, 2023 (the "Maturity Date"). In the event that within 12 months of the Issuance Date, the Maker shall not ...have consummated an initial public offering of its Common Stock and the listing or trading of its Common Stock on a "Qualified Securities Market", as defined below (the "IPO"). (b) Interest. Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual rate of ten percent (10%) (the "Interest Rate") and all accrued interest shall be fully paid on the Maturity Date (or sooner as provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding registration and transfers of Notes in cash. View More
Found in Shuttle Pharmaceuticals Holdings, Inc. contract
View All 6 Similar Clauses
General Terms. Unless previously converted into shares of the common stock, $0.00001par value, of Shuttle Pharma or the common stock of any successor in interest to the Maker (each the "Common Stock") as contemplated hereby, this Note, together with all accrued interest hereon at the Interest Rate, shall be due and payable on the earlier of the Company's completion of its IPO (as defined below) or July December 31, 2023 2024 (the "Maturity Date"). In the event that within 12 months of the Issuance Date, the Ma...ker shall not have consummated an initial public offering of its Common Stock and the listing or trading of its Common Stock on a "Qualified Securities Market", as defined below (the "IPO"). "IPO") or other "Liquidity Event" (hereinafter defined), the Maker may elect either (a) up on thirty (30) days prior written notice to the Holder, elect to prepay all of the principal amount of the Note and accrued interest hereon, subject to the Holder's right to convert the Note into Common Stock during such thirty (30) day period, or (b) if the Maker does not prepay the entire principal amount of the Note or the remaining principal amount of the Note, this Note will automatically increase to 110% of the original or unpaid portion of the outstanding principal amount. (b) Interest. Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual rate of ten six percent (10%) (6%) (the "Interest Rate") and all accrued interest shall be fully paid on the Maturity Date (or sooner as provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding registration and transfers of Notes in cash. However, in the event of an optional or mandatory conversion of the Note into shares of Common Stock (as provided herein), all accrued interest on the Principal subject to such conversion shall be waived. View More
Found in Shuttle Pharmaceuticals Holdings, Inc. contract
General Terms. Unless previously converted into shares of the common stock, $0.00001par $0.001 par value, of Shuttle Pharma Cadrenal Therapeutics or the common stock of any successor in interest to the Maker (each the "Common Stock") as contemplated hereby, this Note, together with all accrued interest hereon at the Interest Rate, shall be due and payable on three years from the earlier date of the Company's completion last closing of its IPO (as the Notes, as hereinafter defined below) or July 31, 2023 (the i...n Section 3(g)(iv)(the "Maturity Date"). In the event that within 12 18 months of the Issuance Date, the Maker shall not have consummated an initial public offering of its Common Stock and the listing or trading of its Common Stock on a "Qualified Securities Market", as defined below (the "IPO"). "IPO") or other "Liquidity Event" (hereinafter defined), the Maker may elect either (a) up on twenty (20) days prior written notice to the Holder, to prepay all of the Outstanding Balance of the Note and accrued interest hereon, or (b) if the Maker does not prepay the entire principal amount of the Note or the remaining principal amount of the Note, this Note will automatically increase to 110% of the original or unpaid portion of the outstanding principal amount. (b) Interest. Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual rate of ten six percent (10%) (6%) (the "Interest Rate") and all accrued interest shall be fully paid on the Maturity Date (or sooner as provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding registration and transfers of Notes in cash. However, in the event of an optional or mandatory conversion of the Note into shares of Common Stock (as provided herein), all accrued interest on the principal subject to such conversion shall be waived. View More
Found in Cadrenal Therapeutics, Inc. contract
General Terms. (a) Payment of Principal. Unless previously converted into shares of the common stock, $0.00001par $0.125 par value, of Shuttle Pharma RVeloCITY or the common stock of any successor in interest to the Maker (each the "Common Stock") as contemplated hereby, this Note, together with all accrued interest hereon at the Interest Rate, shall be due and payable on the earlier of the Company's completion of its IPO (as defined below) or July 31, 2023 [November , 2024] (the "Maturity Date"). In the event... that within 12 months of the Issuance Date, the Maker shall not have consummated an initial public offering of its Common Stock and the listing or trading of its Common Stock on a "Qualified Securities Market", as defined below (the "IPO"). "IPO") or other "Liquidity Event" (hereinafter defined), the Maker may elect either (a) up on thirty (30) days prior written notice to the Holder, elect to prepay all of the principal amount of the Note and accrued interest hereon, subject to the Holder's right to convert the Note into Common Stock during such thirty (30) day period, or (b) if the Maker does not prepay the entire principal amount of the Note or the remaining principal amount of the Note, this Note will automatically increase to 110% of the original or unpaid portion of the outstanding principal amount. 1 (b) Interest. Interest shall accrue from the Issuance Date on the Original Principal Amount or other outstanding Principal at an annual rate of ten six percent (10%) (6%) (the "Interest Rate") and all accrued interest shall be fully paid on the Maturity Date (or sooner as provided herein) to the Holder or its assignee in whose name this Note is registered on the records of the Maker regarding registration and transfers of Notes in cash. However, in the event of an optional or mandatory conversion of the Note into shares of Common Stock (as provided herein), all accrued interest on the Principal subject to such conversion shall be waived. View More
Found in RVELOCITY, INC. contract
View Variations (6)
General Terms. 9.3.Notices. 9.4.Assignment. 9.5.Interpretation. 9.6.Counterparts; Exhibits.
Found in Alpine 4 Technologies Ltd. contract
General Terms. 9.2.Governing Law. 9.3.Notices. 9.4.Assignment. 9.5.Interpretation. 9.6.Counterparts; Exhibits.
Found in Alpine 4 Technologies Ltd. contract
View Variation